Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 6/12/2025

Prostate Cancer Treatment Guidelines

Introduction to Treatment Options

  • The American College of Clinical Oncology recommends chemotherapy regimens including docetaxel, abiraterone, enzalutamide, or apalutamide, each administered with androgen deprivation therapy (ADT), for patients with advanced prostate cancer, with selection based on disease volume, risk factors, and patient characteristics 1

High-Volume Disease Treatment

  • For high-volume disease (HVD), docetaxel plus ADT should be offered to men with metastatic noncastrate prostate cancer as defined by CHAARTED (≥4 bone metastases with ≥1 outside spine/pelvis and/or visceral disease) 1
  • High-volume disease is defined as ≥4 bone metastases with ≥1 outside spine/pelvis and/or visceral disease 1

Treatment Regimens and Dosage

  • The recommended regimen for high-volume disease is six doses of docetaxel at 75 mg/m² administered every 3 weeks with or without prednisone 1
  • Abiraterone 1,000 mg with prednisone or prednisolone 5 mg once daily is recommended for high-risk de novo metastatic noncastrate prostate cancer per LATITUDE criteria 1

Treatment Considerations

  • Docetaxel is associated with greater toxicity than androgen-targeted therapies, but treatment course is relatively short and generally covered by insurance 1
  • Abiraterone has less acute toxicity but requires continuous administration with monitoring for side effects 1

Castration-Resistant Prostate Cancer Treatment

  • First-line chemotherapy for patients who progress to castration-resistant prostate cancer (CRPC) is docetaxel 75 mg/m² every 3 weeks with prednisone 5 mg twice daily 3
  • For men with CRPC and bone metastases, zoledronic acid every 3-4 weeks is recommended to prevent skeletal complications 3

Response Assessment and Treatment Duration

  • PSA response (≥50% decrease) occurs in approximately half of patients treated with docetaxel, but formal response assessment should be delayed until approximately 12 weeks (4 cycles) 4
  • At least 2 cycles (6 weeks) of docetaxel should be administered before making efficacy decisions 4
  • The duration of therapy is based on assessment of benefit and toxicities; in pivotal trials, patients received up to 10 cycles if no progression or prohibitive toxicities occurred 3

Disease Volume Assessment and Monitoring

  • Disease volume assessment is critical, as docetaxel benefit is primarily in high-volume disease; inappropriate use in low-volume disease exposes patients to toxicity without proven survival benefit 1
  • Clinical benefit should be assessed considering symptoms and performance status alongside PSA measurements 4
  • Early discontinuation before adequate trial (minimum 2 cycles) may miss potential benefit 4

REFERENCES

2

nccn clinical practice guidelines in oncology: prostate cancer. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2010

3

Management of Castration-Resistant Prostate Cancer with Docetaxel [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025